Table 1.
Patient group |
|||
---|---|---|---|
Parameter | CHD (n = 391) | Control (n = 140) | Statistical significance |
Age, years | 62 (30–83) | 59 (31–81) | P = 0.001 |
Sex, male | 271 (69.3%) | 58 (41.4%) | P < 0.001 |
Diabetes | 122 (31.2%) | 21 (15.0%) | P < 0.001 |
Hypertension | 266 (68.0%) | 80 (57.1%) | P = 0.008 |
Smoking | 220 (56.3%) | 57 (40.7%) | P < 0.001 |
BMI, kg/m2 | 25.9 (18.4–48.6) | 25.4 (16.9–34.1) | NS |
Total cholesterol, mmol/l | 4.58 (0.86–8.07) | 4.59 (0.92–10.03) | NS |
Triglycerides, mmol/l | 1.52 (0.48–11.69) | 1.25 (0.44–16.31) | P = 0.001 |
HDL-C, mmol/l | 1.25 (0.33–3.33) | 1.38 (0.79–2.93) | P = 0.002 |
LDL-C, mmol/l | 2.55 (0.24–5.34) | 2.49 (0.72–4.81) | NS |
Lipoprotein(a), g/l | 0.20 (0.02–0.92) | 0.20 (0.05–0.97) | NS |
Fibrinogen, g/l | 3.45 (1.63–8.72) | 3.28 (0.96–7.68) | P = 0.003 |
CRP, ng/l | 0.82 (0–52.07) | 0.36 (0.02–11.30) | P < 0.001 |
Lp-PLA2, µg/l | 250.6 (8.8–762.9) | 219.2 (1.6–620.0) | P = 0.001 |
≥292 µg/la | 127 (32.5%) | 30 (21.4%) | P = 0.015 |
Probucol treatment | 49 (12.5%) |
Data presented as median (range) or n (%) prevalence.
BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein; Lp-PLA2, lipoprotein-associated phospholipase A2.
292 µg/l represents the upper quartile of Lp-PLA2 concentration in all patients.
NS, no statistically significant between-group difference (P > 0.05; Student’s independent t-test).